Regulatory Relief To Promote Domestic Production of Critical Medicines

On May 5, 2025, President Donald Trump signed an executive order aimed at boosting domestic production of critical medicines by streamlining regulatory processes. The order directs federal agencies, including the FDA and EPA, to eliminate unnecessary regulations and expedite reviews for pharmaceutical manufacturing, thereby reducing the time and complexity involved in building and expanding facilities in the U.S. This move could enhance national security by ensuring a more resilient supply chain for essential medicines, but it may also face scrutiny over potential environmental and safety oversight reductions.